Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

BioSim M2M: Molecules to Medicine

Project description

AI-based drug development

Despite rising demand for new pharmaceutical drugs, the associated high cost significantly reduces the success of research and development efforts. New digital technologies, including AI, are being employed to predict the structure and effectiveness of new drug molecules. The EIC-funded biosim m2m project builds on a breakthrough technology that can reliably predict the most stable crystal structure of a drug compound. Traditional polymorph analysis involves lengthy, labour-intensive experimentation with low success rates. By selecting the best crystalline form for manufacturing and therapeutic use, biosim m2m technology is expected to optimise drug formulations and prevent late-stage failures of selected compounds.

Objective

BioSimulytics has developed breakthrough technology combining quantum physics, computational chemistry, machine learning, and high-performance computing to boost the success rates of pharmaceutical R&D. The BioSimulytics invention (patent EP3948877A1), is being applied to crystal structure prediction (CSP) for determining the most stable crystal structure or polymorph of a drug compound, as well as the most stable binding poses in protein-ligand complexes.
Existing state-of-the-art techniques for polymorph analysis require long and painstaking experimentation by material scientists with uncertain results (<1% success rates). BioSim M2M will reduce the time to find the most stable crystal structures of a molecule from 3 months to 3 weeks and reduce candidate experiments from 400 to 40. As a result, BioSim M2M will contribute to the Pharmaceutical Strategy for Europe by helping to ensure that patients have access to high quality, effective, and safe medicines.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

BIOSIMULYTICS LIMITED
Net EU contribution
€ 2 499 525,00
Address
NOVAUCD, BELFIELD INNOVATION PARK,UNIVERSITY COLLEGE DUBLIN
D04 V2P1 DUBLIN
Ireland
SME
Yes
Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 570 750,00